AbbVie Inc.

AbbVie Inc. is a global, research-driven biopharmaceutical company that develops and markets innovative therapies primarily for treating serious health conditions. It emerged as an independent entity following its split from Abbott Laboratories in 2013. AbbVie's core focus lies in developing solutions for complex diseases across key therapeutic areas such as immunology, oncology, virology, and neuroscience. A significant portion of the company's revenue and growth has been driven by its flagship drug, Humira, which is utilized in the treatment of autoimmune diseases and conditions like rheumatoid arthritis and Crohn’s disease. Beyond Humira, AbbVie has expanded its product lineup with the acquisition of Allergan, bringing on board Botox and other ophthalmology and neuroscience treatments. AbbVie's strategic emphasis on advancing its research pipeline and broader product portfolio solidifies its significant presence in the pharmaceutical sector, addressing critical health challenges globally and contributing to the enhancement of patient lives through innovative therapeutic solutions.